Background illustration for clinical trials search

Pancreatic Cancer Clinical Trials

Browse 1,722 pancreatic cancer clinical trials enrolling across the United States and Canada. Search by city or state to find one near you.

Filter
1

A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer

for
Hepatocellular Carcinoma (HCC), Cholangiocarcinoma,
Location: Duarte CA
Sponsor: City of Hope Medical Center

Sex: All

Age: 18+

Code: NCT07224750

Recruiting

Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Resistant Ovarian Cancer

for
Metastatic Malignant Solid Neoplasm,
Location: Boston MA, Deerfield Beach FL, Coral Gables FL,
Sponsor: National Cancer Institute (NCI)

Sex: All

Age: 18+

Code: NCT04585958

Phase 1, Recruiting

Combination Therapy in Patients With Localized Pancreatic Ductal Adenocarcinoma

for
Pancreatic Ductal Adenocarcinoma
Location: Lake Success NY, New York NY, Philadelphia PA,
Sponsor: Gulam Manji

Sex: All

Age: 18+

Code: NCT06048484

Phase 2, Recruiting

Safety of Combining Irinotecan With 5-FU, Leucovorin/Folinic Acid, Oxaliplatin, and Docetaxel Chemotherapies

for
Pancreatic Adenocarcinoma,
Location: Chicago IL
Sponsor: University of Chicago

Sex: All

Age: 18+

Code: NCT04361708

Phase 1, Recruiting

Belzutifan/MK-6482 for the Treatment of Advanced Pheochromocytoma/Paraganglioma (PPGL), Pancreatic Neuroendocrine Tumor (pNET), Von Hippel-Lindau (VHL) Disease-Associated Tumors, Advanced Gastrointestinal Stromal Tumor (wt GIST), or Solid Tumors With HIF-2α Related Genetic Alterations (MK-6482-015)

for
Pheochromocytoma/Paraganglioma, Pancreatic Neuroendocrine Tumor,
Location: Boston MA, Baltimore MD, Bethesda MD, Toronto,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 12+

Code: NCT04924075

Phase 2, Recruiting

Interested in new trials?

Get alerts for new trials in your area by subscribing now

Subscriber Image

Safety of Cyberknife in Patients With Borderline Resectable or Locally Advanced Pancreatic Adenocarcinoma

for
Pancreas Adenocarcinoma
Location: Pennington NJ
Sponsor: Capital Health System, Inc

Sex: All

Age: 18+

Code: NCT04998552

Recruiting

A Study of BMS-986340 as Monotherapy and as Combination Therapy in Participants With Advanced Solid Tumors

for
Cervical Cancer,
Location: Hackensack NJ, Montreal, Hamilton, Nashville TN,
Sponsor: Bristol-Myers Squibb

Sex: All

Age: 18+

Code: NCT04895709

Phase 1, Phase 2, Recruiting
New

A Study to Learn About the Study Medicine Called PF-08098488 in People With Advanced Solid Tumors.

for
Pancreatic Ductal Adenocarcinoma, Esophageal Cancer,
Location: Grand Rapids MI, Nashville TN, San Antonio TX
Sponsor: Pfizer

Sex: All

Age: 18+

Code: NCT07903415

Phase 1, Recruiting
New

Lorigerlimab (MGD019) in Patients With Pancreatic Adenocarcinoma and Homologous Recombination Deficiency

for
Pancreatic Adenocarcinoma, Homologous Recombination Deficiency
Location: Miami FL
Sponsor: University of Miami

Sex: All

Age: 18+

Code: NCT07565155

Phase 2, Recruiting
New

A Phase 1 Trial Of Safety And Initial Efficacy Of Vagal Nerve Blockade For Cancer-Induced Cachexia In Patients With Metastatic Pancreatic Adenocarcinoma

for
Metastatic Pancreatic Adenocarcinoma
Location: Houston TX
Sponsor: M.D. Anderson Cancer Center

Sex: All

Age: 18+

Code: NCT07700212

Phase 1, Recruiting

Using 18F-FAPI PET to Detect Metastatic Disease in Patients That Have Pancreatic Ductal Adenocarcinoma (PDAC)

for
Pancreatic Ductal Adenocarcinoma (PDAC)
Location: Boston MA, Worcester MA, New York NY, Philadelphia PA,
Sponsor: SOFIE

Sex: All

Age: 18+

Code: NCT07217717

Phase 3, Recruiting

A Clinical Study of Calderasib (MK-1084) in People With Advanced Solid Tumors (MK-1084-014)

for
Neoplasm Malignant
Location: New Brunswick NJ, Montreal, Baltimore MD, Ottawa,
Sponsor: Merck Sharp & Dohme LLC

Sex: All

Age: 18+

Code: NCT07209111

Phase 2, Recruiting

First-in-Human Study of PLX-61639 in Locally Advanced or Metastatic Solid Tumors

for
Esophageal Squamous Cell Carcinoma, Gastric Adenocarcinoma,
Location: Boston MA, New York NY, Fairfax VA, Durham NC,
Sponsor: Plexium, Inc.

Sex: All

Age: 18+

Code: NCT07284186

Phase 1, Recruiting

A Study to Investigate the Pharmacokinetics and Safety of Subcutaneous Rilvegostomig in Adult Participants With Advanced Solid Tumors Previously Treated With Standard of Care Therapy

for
Advanced Solid Tumors
Location: Fairfax VA, Huntersville NC, San Antonio TX
Sponsor: AstraZeneca

Sex: All

Age: 18+

Code: NCT07161414

Phase 1, Recruiting

An Artificial Intelligence-Powered Supportive Care Chatbot to Address the Supportive Care Needs of Young Adult Cancer Survivors

for
Hematopoietic and Lymphatic System Neoplasm,
Location: Ann Arbor MI
Sponsor: University of Michigan Rogel Cancer Center

Sex: All

Age: 18 - 39

Code: NCT07772596

Recruiting

A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies

for
Advanced Solid Tumors, Ewing Sarcoma,
Location: Boston MA, New York NY, Houston TX, Duarte CA,
Sponsor: SEED Therapeutics, Inc.

Sex: All

Age: 16+

Code: NCT07197554

Phase 1, Recruiting

Cannabis Use Registry to Improve Overall Understanding of Symptoms (CURIOUS)

for
Cannabis Use, Cancer
Location: Saint Louis Park MN
Sponsor: HealthPartners Institute

Sex: All

Age: 18+

Code: NCT07227324

Recruiting

A Study of STRO-004 in Adults With Refractory/Recurrent Metastatic Cancer

for
Head and Neck Squamous Cell Carcinoma HNSCC,
Location: Boston MA, New York NY, Washington D.C. DC, Fairfax VA,
Sponsor: Sutro Biopharma, Inc.

Sex: All

Age: 18+

Code: NCT07227168

Phase 1, Recruiting

Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma

for
Metastatic Pancreatic Adenocarcinoma,
Location: Charleston SC
Sponsor: Medical University of South Carolina

Sex: All

Age: 18+

Code: NCT07076212

Phase 2, Recruiting

JAB-23E73 in Adult Participants With Advanced Solid Tumors With KRAS Alteration

for
Advanced Solid Tumors
Location: Cleveland OH, St Louis MO, Rochester MN,
Sponsor: Jacobio Pharmaceuticals Co., Ltd.

Sex: All

Age: 18+

Code: NCT06973564

Phase 1, Phase 2, Recruiting

What is pancreatic cancer?

The pancreas sits deep behind the stomach and makes both digestive enzymes and hormones like insulin. About 92 percent of pancreatic cancers start in the enzyme making cells, and this page is mostly about those. The other 8 percent are neuroendocrine tumors, which grow more slowly, have their own trials, and a five year survival of 72 percent against 8 percent. The pancreas gives no early warning. Jaundice, back pain, weight loss and new diabetes usually appear only after the cancer has grown or spread, and fewer than 20 percent of people can have surgery at diagnosis.

Smoking roughly doubles the risk, and type 2 diabetes, extra weight, chronic pancreatitis and family history raise it. About 10 percent of cases come from inherited mutations, so guidelines now recommend genetic testing for everyone diagnosed. That can change treatment and flag relatives who should be watched. The hope comes from biology. More than 90 percent of pancreatic cancers carry a KRAS mutation. That target was called undruggable for decades. Now several RAS inhibitors are in trials, with the first Phase 3 studies recruiting. Pancreatic cancer shares risk factors with type 2 diabetes and inherited genes with breast and ovarian cancer.

Article preview image

Our guide to new treatments for pancreatic cancer covers what has been approved and what is being tested.

Research Paving The Way To A New Treatment For Pancreatic Cancer

Types of pancreatic cancer clinical trials

Who can participate in pancreatic cancer clinical trials?

What causes pancreatic cancer?

The stages of pancreatic cancer, and why they matter for trials

How to enroll in a pancreatic cancer clinical trial